23 results on '"Sofia M. Shea"'
Search Results
2. Supplementary Methods from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
3. Supplementary Table S1. Toxicities. from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
4. Supplementary Figure 3 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
5. Supplementary Figure 1 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
6. Data from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
7. Supplementary Text. from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
8. Supplementary Figure 2 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
9. Supplementary Figure 3. Selected RPPA data from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
10. Supplementary Figure S1. Lymphocyte counts from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
11. Supplementary Tables 1-4, Figure 1 from Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
12. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins
13. Cutaneous side effects of vemurafenib: a case report and discussion
14. Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
15. Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients
16. Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
17. The role of capsaicin in dermatology
18. The Role of Capsaicin in Dermatology
19. Activation, Dysfunction and Retention of T Cells in Vaccine Sites after Injection of Incomplete Freund’s Adjuvant, With or Without Peptide
20. Short-term application of doxorubicin chemotherapy immunosuppressive side effects for composite tissue allotransplantation
21. Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging Manual
22. Molecular Diagnostics in Dermatology and Dermatopathology
23. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.